Decision AI - Pharma, CPG & Manufacturing bet - What & Why ?

Since inception of DecisionX AI ,Here's a belief we held plainly.

The purpose of AI in a business is to deliver disproportionate ROI and a real competitive advantage, not a marginal one. Not to be impressive. Not to be present. If it isn't disproportionate, it's just another piece of technology - interesting, maybe, but not transformative.

So we asked ourselves a different question: where is the ratio of value to effort the widest? Where, if something is genuinely hard, the payoff has to be worth it? We built the most advanced Self Learning, Causal - Decision infra and then came the hard choice - Where to focus ? We went looking for our hard last. 100+ Demos later in April 2026, we had enough signals to call a verdict. It turned out to be Pharma and CPG.

In most industries, AI adoption is a change-management cost you pay for a value gain. In Pharma and CPG, that same change-management effort unlocks something disproportionate - value that goes beyond top line and bottom line into something closer to a structural competitive advantage.

We look at industry choice through two lenses, and they don't tell the same story.

Lens one: potential annual revenue.

Here's the honest picture of where the industry itself estimates the opportunity sits, across sectors:

Worth being straight about what this chart shows and doesn't. Pharma and life sciences carry the smallest absolute number here : $60-110B, well behind Retail & CPG's $400-660B, and behind Banking and High Tech too. That's not an argument against the bet; it's a reason to be precise about it. Pharma's number is smaller because the industry itself is smaller and more concentrated, not because the value-per-decision is thin and this chart doesn't even capture the manufacturing-specific value pool sitting inside batch review, deviation RCA, and CAPA, which McKinsey tracks separately.

Lens two: competitive advantage.

Revenue potential tells you how big the pool is. It doesn't tell you how hard that pool is to defend once you're in it. For that, we score industries on a second, simpler question: how much of the advantage is actually protectable - by regulatory barrier, by proprietary and tribal data that can't be scraped or synthesised, and by depth of workflow integration. This isn't a published index; it's our own composite framework, built on factors the AI-defensibility research community has converged on as the real sources of moat in 2026.

Flip the two lenses side by side, and the rationale for our choice becomes clear. Pharma has the smaller revenue pool, but the wider moat, the kind of advantage that compounds the longer you hold it, because it's built on regulatory depth, tribal knowledge, and trust earned over years, not a feature that ships faster. That's exactly the value-to-effort ratio we went looking for: not the biggest opportunity, but the one most worth building for the long run.

But that ratio comes with a cost. The challenge here is genuinely multi-dimensional. It isn't one hard problem - it's three, stacked on top of each other:

1. Technology that can actually be trusted in an environment where a wrong answer isn't embarrassing, it's dangerous.
2. A product that delivers real ROI, not a demo that impresses in a boardroom and produces nothing measurable six months later.
3. A company that genuinely understands adoption - the specific, unglamorous mechanics of change management inside Pharma and CPG, not change management in the abstract.

Most AI vendors solve for one of these. Almost none solve for all three at once. That's the gap we're building into.

What if a molecule moved through development years faster, not because the science changed, but because the decisions around it did? Drug development still averages 10-15 years and, by recent estimates, $700 million to $2.6 billion per approved drug and a lot of that cost is decision friction, not science.

What if a quality deviation that used to take days of back-and-forth got root-caused before the shift ended? What if the same intelligence that protects patient safety also protected margin, because in these industries, safety and efficiency run through the same decision?

That's the bet, not because these markets are easy, but because purpose, ROI, and value all point the same direction. If it works here, it probably works everywhere else too.

The Three Dimensions of the AI Challenge

a) AI that can actually be trusted. These industries are regulated, and they don't forgive. A hallucinated answer in a marketing tool is embarrassing; the same in a batch deviation review is a different category of problem - the FDA and EMA have both issued guidance in the last year demanding rigorous validation for AI in drug development. A 2025 survey found 44% of organisations had experienced negative consequences from generative AI, averaging $4.4 million per incident. Nobody adopts a tool because it's clever - they adopt it because it's right, consistently, when it matters.

b) A product that actually delivers ROI. The data was never built for this. Roughly 80% of data across healthcare, life sciences, and industrial operations is unstructured, and an estimated 60-70% of enterprise data goes unused entirely, not for lack of value, but because nobody built the pipeline to use it. A product that can't turn that mess into a usable, trustworthy answer will never show up in the P&L, no matter how good the demo looks.

c) A company that understands adoption in this specific world. Even with the technology and the product right, you're asking real people - QA leads, plant supervisors, commercial teams to reimagine how they work and trust a system they didn't build. Change management in Pharma and CPG isn't generic change management; it's shaped by regulatory sign-off chains, tribal knowledge, and decades of institutional caution. Get this wrong, and the best technology in the world sits unused.

Tribal Knowledge: The Part That's Actually Hard

Solving the data problem gets you halfway. The harder half is what the data doesn't say out loud. The real expertise - why a deviation pattern means what it means - usually lives in someone who's run that process for fifteen years. Not in a system. In a person.

That knowledge is walking out the door on a clock:

• Roughly a quarter of the manufacturing workforce is 55 or older, and retirements have accelerated sharply. You can't capture it with a prompt.
• It takes real structure, a state graph encoding how things relate, what causes what, and how that shifts over time. Causality matters more here than almost anywhere else: correlation without causality produces a confident, wrong answer - the one failure mode these industries cannot afford. One thing I feel strongly about: that knowledge belongs to the companies who spent decades building it. Our job isn't to own it. It's to build the structure that lets them use it.

Why "Data Ontology" Alone Isn't the Whole Answer

We're not the only ones saying "ontology" out loud. Databricks and tools built on it - Unity Catalog, OntoBricks, Timbr - turn tables into a governed semantic layer people and agents can query. But that's a Data Ontology defined by what a table means, how it joins another, who owns it. Necessary, not sufficient.

What it misses: Domain Ontology (what a "batch" or "deviation" actually means, as business logic, not schema), Process Ontology (how work flows, who owns which handoff), and Decision Ontology (what a Qualified Person needs to release a batch, what causal chain links a deviation to its root cause, the layer that turns data into a decision AI can stand behind).

A schema can't tell you why a Class II deviation on a sterile-fill line means something different than on an oral solid dosage line. That still lives in SOPs and tribal memory, whether the plant makes medicine, food, or industrial parts.

The same structure - Batch, Equipment, Deviation, CAPA, Release Decision ; maps almost directly across CPG and manufacturing too, which is exactly why it's worth building once, deeply.

Where We're Actually Headed

We're not chasing standalone use cases. We're going deeper into three places where decisions compound into revenue and margin:

Commercial Excellence, R&D Excellence, and Manufacturing Excellence, across Pharma, CPG, and manufacturing.

Commercial is where a spend or pricing decision shows up in the P&L within a quarter. R&D has the most compounding upside, a decade-plus timeline means even small reductions in decision friction pay back many times over. Manufacturing is where stakes are most immediate -decisions made under real time pressure with regulatory consequences.

But "where we're headed" isn't just a choice of pillar. It's a sequencing decision too, because impact alone doesn't tell you what to build first. We triage on three axes: how big the impact is, how ready the underlying data actually is, and how heavy the change management lift will be. Here's how we think about it:

Commercial Excellence sits closest to "now" - the data is comparatively cleaner (CRM, sales, and spend systems are further along than lab notebooks or plant logs), and the change management lift, while real, is lighter than asking a QA team to trust an AI on a release decision.

Manufacturing and R&D both carry high impact and high change-management effort, but for different reasons - Manufacturing's barrier is largely tribal knowledge and floor-level trust, while R&D's barrier is genuinely lower near-term data readiness, given how much of its knowledge lives in unstructured lab records and hasn't been touched yet.

We're building all three with the same seriousness, but different lens. For R&D & Manufacturing, we are building for how to accelerate the Data & AI readiness for high provenance. For Commercial we are building how the ready infra can be fastest translated into top line & bottom line gains. One connected brain - that powers AI transformation within these.

Where This Leaves Us

We didn't pick these industries because they were easy to sell - they've been the hardest conversations we've had. We picked them because the case for AI here has to be made honestly, and the reward, if you earn the trust, is genuinely disproportionate.

And to be clear about what we're building: we don't think of ourselves as an AI tool provider to Pharma and CPG. Tools get bought, evaluated, and occasionally used. We're building to be the driver of AI transformation in these industries - the company a CEO or CDO calls when the goal isn't a pilot, it's a P&L number that actually moves, sustained through the change management, the trust-building, and the years it takes to earn it. That's a bigger bet on ourselves than "provide a good product." We're comfortable with that.

More soon on the ontology stack itself, and an AI guide for leaders across these industries. If you lead decisions inside Pharma, CPG, or Manufacturing, I'd like to know where this matches what you're living - reply or DM me directly.